JP2009514894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009514894A5 JP2009514894A5 JP2008539114A JP2008539114A JP2009514894A5 JP 2009514894 A5 JP2009514894 A5 JP 2009514894A5 JP 2008539114 A JP2008539114 A JP 2008539114A JP 2008539114 A JP2008539114 A JP 2008539114A JP 2009514894 A5 JP2009514894 A5 JP 2009514894A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- ring
- cor
- compound
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 44
- 150000001875 compounds Chemical class 0.000 claims 43
- 229910052757 nitrogen Inorganic materials 0.000 claims 31
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 28
- 125000005842 heteroatom Chemical group 0.000 claims 28
- 229910052760 oxygen Inorganic materials 0.000 claims 28
- 239000001301 oxygen Substances 0.000 claims 28
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 27
- 229910052717 sulfur Inorganic materials 0.000 claims 27
- 239000011593 sulfur Substances 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 25
- 229910052736 halogen Inorganic materials 0.000 claims 24
- 150000002367 halogens Chemical class 0.000 claims 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 229920006395 saturated elastomer Polymers 0.000 claims 19
- 125000001931 aliphatic group Chemical group 0.000 claims 18
- 125000002950 monocyclic group Chemical group 0.000 claims 15
- 125000000464 thioxo group Chemical group S=* 0.000 claims 15
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 14
- 150000007824 aliphatic compounds Chemical class 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000002619 bicyclic group Chemical group 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- 150000002431 hydrogen Chemical group 0.000 claims 7
- 125000002723 alicyclic group Chemical group 0.000 claims 6
- 230000001580 bacterial effect Effects 0.000 claims 6
- -1 Ar 3 is —R J Chemical group 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 150000002222 fluorine compounds Chemical class 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 241000194033 Enterococcus Species 0.000 claims 2
- 241000194032 Enterococcus faecalis Species 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 241000606768 Haemophilus influenzae Species 0.000 claims 2
- 241000590002 Helicobacter pylori Species 0.000 claims 2
- 241000588621 Moraxella Species 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940047650 haemophilus influenzae Drugs 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 229940037467 helicobacter pylori Drugs 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 206010034674 peritonitis Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 2
- YBBLOADPFWKNGS-UHFFFAOYSA-N 1,1-dimethylurea Chemical compound CN(C)C(N)=O YBBLOADPFWKNGS-UHFFFAOYSA-N 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000004672 Cardiovascular Infections Diseases 0.000 claims 1
- 208000014912 Central Nervous System Infections Diseases 0.000 claims 1
- 108010065152 Coagulase Proteins 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 241000588914 Enterobacter Species 0.000 claims 1
- 208000001860 Eye Infections Diseases 0.000 claims 1
- 208000002633 Febrile Neutropenia Diseases 0.000 claims 1
- 206010017964 Gastrointestinal infection Diseases 0.000 claims 1
- 206010048461 Genital infection Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- 241000589242 Legionella pneumophila Species 0.000 claims 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 241000588655 Moraxella catarrhalis Species 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 208000005141 Otitis Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 241000588769 Proteus <enterobacteria> Species 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 241000607715 Serratia marcescens Species 0.000 claims 1
- 206010062255 Soft tissue infection Diseases 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- 241000193996 Streptococcus pyogenes Species 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 208000006374 Uterine Cervicitis Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 229940065181 bacillus anthracis Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 206010008323 cervicitis Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 208000019836 digestive system infectious disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000019258 ear infection Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 229940032049 enterococcus faecalis Drugs 0.000 claims 1
- 230000007717 exclusion Effects 0.000 claims 1
- 208000011323 eye infectious disease Diseases 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 229940115932 legionella pneumophila Drugs 0.000 claims 1
- 229940013390 mycoplasma pneumoniae Drugs 0.000 claims 1
- 206010033072 otitis externa Diseases 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 150000003672 ureas Chemical class 0.000 claims 1
- 208000000143 urethritis Diseases 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
- 0 C*(C)(*)c1ccccn1 Chemical compound C*(C)(*)c1ccccn1 0.000 description 22
- UQFQONCQIQEYPJ-UHFFFAOYSA-N C[n]1nccc1 Chemical compound C[n]1nccc1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 2
- LNJMHEJAYSYZKK-UHFFFAOYSA-N Cc1ncccn1 Chemical compound Cc1ncccn1 LNJMHEJAYSYZKK-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N O=C1NCCC1 Chemical compound O=C1NCCC1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- XCBKPJMTRNNEMG-SNAWJCMRSA-N C/C(/I)=C\C(N(C)C)O Chemical compound C/C(/I)=C\C(N(C)C)O XCBKPJMTRNNEMG-SNAWJCMRSA-N 0.000 description 1
- HZHMUSZMPOUQQA-ONEGZZNKSA-N C/C(/I)=C\C(N=C)=O Chemical compound C/C(/I)=C\C(N=C)=O HZHMUSZMPOUQQA-ONEGZZNKSA-N 0.000 description 1
- JBZGCQNNPKPPOT-UHFFFAOYSA-N C=CNC(Nc1cc(cc(C(CCN2Cc3ccccc3)CC2=O)cc2-[n]3nccc3)c2[nH]1)=O Chemical compound C=CNC(Nc1cc(cc(C(CCN2Cc3ccccc3)CC2=O)cc2-[n]3nccc3)c2[nH]1)=O JBZGCQNNPKPPOT-UHFFFAOYSA-N 0.000 description 1
- XBYRBOUMUJTELC-ARJAWSKDSA-N CC(/C=C\NN)=C Chemical compound CC(/C=C\NN)=C XBYRBOUMUJTELC-ARJAWSKDSA-N 0.000 description 1
- NGETUESZTOUZJV-UHFFFAOYSA-N CC(C)C(CCN1Cc2ccccc2)CC1=O Chemical compound CC(C)C(CCN1Cc2ccccc2)CC1=O NGETUESZTOUZJV-UHFFFAOYSA-N 0.000 description 1
- GFWZPTGIVKRQNM-UHFFFAOYSA-N CC(C)CC(NC)=O Chemical compound CC(C)CC(NC)=O GFWZPTGIVKRQNM-UHFFFAOYSA-N 0.000 description 1
- HFEJDORPCWHHEE-UHFFFAOYSA-N CC(CC(N(C)C)=O)N(C)C Chemical compound CC(CC(N(C)C)=O)N(C)C HFEJDORPCWHHEE-UHFFFAOYSA-N 0.000 description 1
- PKDPUENCROCRCH-UHFFFAOYSA-O CC(N1CC[NH2+]CC1)=O Chemical compound CC(N1CC[NH2+]CC1)=O PKDPUENCROCRCH-UHFFFAOYSA-O 0.000 description 1
- QPSJVASZBYKDFM-ISTTXYCBSA-N CC/C(/N)=C/C=C\C=C Chemical compound CC/C(/N)=C/C=C\C=C QPSJVASZBYKDFM-ISTTXYCBSA-N 0.000 description 1
- SKUUIUHMAOMKTL-UHFFFAOYSA-N CCCNC(Nc1nc(cc(cc2-c3ncccc3F)C(NC)=O)c2[nH]1)=O Chemical compound CCCNC(Nc1nc(cc(cc2-c3ncccc3F)C(NC)=O)c2[nH]1)=O SKUUIUHMAOMKTL-UHFFFAOYSA-N 0.000 description 1
- BQZHGBONSDMYNH-UHFFFAOYSA-N CCNC(N/C(/C)=N/c(cc(C(CCN1C)CC1=O)cc1-c2ncccc2F)c1N)=O Chemical compound CCNC(N/C(/C)=N/c(cc(C(CCN1C)CC1=O)cc1-c2ncccc2F)c1N)=O BQZHGBONSDMYNH-UHFFFAOYSA-N 0.000 description 1
- KOWPSDVWJSBNFI-UHFFFAOYSA-N CCNC(NC(NC12C)=NC1=CC(C(CCN1Cc3ccccc3)=CC1=O)=CC2[n]1nccc1)=O Chemical compound CCNC(NC(NC12C)=NC1=CC(C(CCN1Cc3ccccc3)=CC1=O)=CC2[n]1nccc1)=O KOWPSDVWJSBNFI-UHFFFAOYSA-N 0.000 description 1
- RHAPDYLFMQCIRL-UHFFFAOYSA-N CCNC(Nc1nc(cc(C)c(F)c2-[n]3nccc3)c2[nH]1)=O Chemical compound CCNC(Nc1nc(cc(C)c(F)c2-[n]3nccc3)c2[nH]1)=O RHAPDYLFMQCIRL-UHFFFAOYSA-N 0.000 description 1
- GPJPQOVGYMSPDQ-UHFFFAOYSA-N CCNC(Nc1nc(cc(C)cc2-c(nccc3)c3F)c2[nH]1)=O Chemical compound CCNC(Nc1nc(cc(C)cc2-c(nccc3)c3F)c2[nH]1)=O GPJPQOVGYMSPDQ-UHFFFAOYSA-N 0.000 description 1
- ZARPSXATBSBTDW-FMIVXFBMSA-N CCNC(Nc1nc(cc(cc2-c3ncccc3F)/C(/C)=C/C(N(C)C)=O)c2[nH]1)=O Chemical compound CCNC(Nc1nc(cc(cc2-c3ncccc3F)/C(/C)=C/C(N(C)C)=O)c2[nH]1)=O ZARPSXATBSBTDW-FMIVXFBMSA-N 0.000 description 1
- FRUVHPZMKYQKRC-DHZHZOJOSA-N CCNC(Nc1nc(cc(cc2-c3ncccc3F)/C(/C)=C/C(NC)=O)c2[nH]1)=O Chemical compound CCNC(Nc1nc(cc(cc2-c3ncccc3F)/C(/C)=C/C(NC)=O)c2[nH]1)=O FRUVHPZMKYQKRC-DHZHZOJOSA-N 0.000 description 1
- AWEQYBJYULIIML-UHFFFAOYSA-N CCNC(Nc1nc(cc(cc2-c3ncccc3F)C(O)=O)c2[nH]1)=O Chemical compound CCNC(Nc1nc(cc(cc2-c3ncccc3F)C(O)=O)c2[nH]1)=O AWEQYBJYULIIML-UHFFFAOYSA-N 0.000 description 1
- WYOYLTADEDNMAW-UHFFFAOYSA-N CCNC(Nc1nc(cc(cc2-c3ncccc3F)C(OC)=O)c2[nH]1)=O Chemical compound CCNC(Nc1nc(cc(cc2-c3ncccc3F)C(OC)=O)c2[nH]1)=O WYOYLTADEDNMAW-UHFFFAOYSA-N 0.000 description 1
- FOUIXBUIXNYFBK-UHFFFAOYSA-N CCNC(Nc1nc(cc(cc2-c3ncccn3)F)c2[nH]1)=O Chemical compound CCNC(Nc1nc(cc(cc2-c3ncccn3)F)c2[nH]1)=O FOUIXBUIXNYFBK-UHFFFAOYSA-N 0.000 description 1
- YNVJGRMCNAEXKA-UHFFFAOYSA-N CCNC(Nc1nc(cc(cc2-c3ncccn3)N(CC3)CC3O)c2[nH]1)=O Chemical compound CCNC(Nc1nc(cc(cc2-c3ncccn3)N(CC3)CC3O)c2[nH]1)=O YNVJGRMCNAEXKA-UHFFFAOYSA-N 0.000 description 1
- YGXOEXJZSLJBHS-UHFFFAOYSA-N CCNC(Nc1nc(cc(cc2-c3ncccn3)NCc3ncccc3)c2[nH]1)=O Chemical compound CCNC(Nc1nc(cc(cc2-c3ncccn3)NCc3ncccc3)c2[nH]1)=O YGXOEXJZSLJBHS-UHFFFAOYSA-N 0.000 description 1
- FZXUVODYYWQZIA-UHFFFAOYSA-N CCNC(Nc1nc(cc(cc2C3=NCC(C)C=N3)N(CCC3)C3=O)c2[nH]1)=O Chemical compound CCNC(Nc1nc(cc(cc2C3=NCC(C)C=N3)N(CCC3)C3=O)c2[nH]1)=O FZXUVODYYWQZIA-UHFFFAOYSA-N 0.000 description 1
- CMYOWLMVJBDAGK-UHFFFAOYSA-N CCNC(Nc1nc2cc(OC)cc(-[n]3nccc3)c2[nH]1)=O Chemical compound CCNC(Nc1nc2cc(OC)cc(-[n]3nccc3)c2[nH]1)=O CMYOWLMVJBDAGK-UHFFFAOYSA-N 0.000 description 1
- NHJYYUYWCDVVQA-UHFFFAOYSA-N CCNCC(Nc1nc(cc(cc2-c3ncccn3)N(CC3)CCN3C(C)=O)c2[nH]1)=O Chemical compound CCNCC(Nc1nc(cc(cc2-c3ncccn3)N(CC3)CCN3C(C)=O)c2[nH]1)=O NHJYYUYWCDVVQA-UHFFFAOYSA-N 0.000 description 1
- LYMIQKSWVRUXMC-UHFFFAOYSA-N CC[IH]N(CC1)CC1[O]=C Chemical compound CC[IH]N(CC1)CC1[O]=C LYMIQKSWVRUXMC-UHFFFAOYSA-N 0.000 description 1
- NRGGMCIBEHEAIL-UHFFFAOYSA-N CCc1ccccn1 Chemical compound CCc1ccccn1 NRGGMCIBEHEAIL-UHFFFAOYSA-N 0.000 description 1
- JUIVBQFWSRPDCV-UHFFFAOYSA-N CN(C)C(NI)=O Chemical compound CN(C)C(NI)=O JUIVBQFWSRPDCV-UHFFFAOYSA-N 0.000 description 1
- JUPQRASMHWFLCX-UHFFFAOYSA-N CP(CN(CCC(C1)N2CC2)C1=O)=C Chemical compound CP(CN(CCC(C1)N2CC2)C1=O)=C JUPQRASMHWFLCX-UHFFFAOYSA-N 0.000 description 1
- NGCXHCGUQHIOLZ-UHFFFAOYSA-N C[n]1nccn1 Chemical compound C[n]1nccn1 NGCXHCGUQHIOLZ-UHFFFAOYSA-N 0.000 description 1
- MWZDIEIXRBWPLG-UHFFFAOYSA-N C[n]1ncnc1 Chemical compound C[n]1ncnc1 MWZDIEIXRBWPLG-UHFFFAOYSA-N 0.000 description 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N Cc1c[nH]cn1 Chemical compound Cc1c[nH]cn1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 1
- PUMREIFKTMLCAF-UHFFFAOYSA-N Cc1c[o]cn1 Chemical compound Cc1c[o]cn1 PUMREIFKTMLCAF-UHFFFAOYSA-N 0.000 description 1
- QMHIMXFNBOYPND-UHFFFAOYSA-N Cc1c[s]cn1 Chemical compound Cc1c[s]cn1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N Cc1ccccn1 Chemical compound Cc1ccccn1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- MXDRPNGTQDRKQM-UHFFFAOYSA-N Cc1cccnn1 Chemical compound Cc1cccnn1 MXDRPNGTQDRKQM-UHFFFAOYSA-N 0.000 description 1
- AGQOIYCTCOEHGR-UHFFFAOYSA-N Cc1ccn[o]1 Chemical compound Cc1ccn[o]1 AGQOIYCTCOEHGR-UHFFFAOYSA-N 0.000 description 1
- LBBKWEDRPDGXPM-UHFFFAOYSA-N Cc1ccn[s]1 Chemical compound Cc1ccn[s]1 LBBKWEDRPDGXPM-UHFFFAOYSA-N 0.000 description 1
- LVILGAOSPDLNRM-UHFFFAOYSA-N Cc1ccncn1 Chemical compound Cc1ccncn1 LVILGAOSPDLNRM-UHFFFAOYSA-N 0.000 description 1
- ZYMHCFYHVYGFMS-UHFFFAOYSA-N Cc1cnc[o]1 Chemical compound Cc1cnc[o]1 ZYMHCFYHVYGFMS-UHFFFAOYSA-N 0.000 description 1
- CAWHJQAVHZEVTJ-UHFFFAOYSA-N Cc1cnccn1 Chemical compound Cc1cnccn1 CAWHJQAVHZEVTJ-UHFFFAOYSA-N 0.000 description 1
- INPPAWCHJHNCAE-UHFFFAOYSA-N Cc1cnncn1 Chemical compound Cc1cnncn1 INPPAWCHJHNCAE-UHFFFAOYSA-N 0.000 description 1
- GVSNQMFKEPBIOY-UHFFFAOYSA-N Cc1n[nH]nc1 Chemical compound Cc1n[nH]nc1 GVSNQMFKEPBIOY-UHFFFAOYSA-N 0.000 description 1
- CUMCMYMKECWGHO-UHFFFAOYSA-N Cc1n[o]cc1 Chemical compound Cc1n[o]cc1 CUMCMYMKECWGHO-UHFFFAOYSA-N 0.000 description 1
- IBANRDPEOYZVGW-UHFFFAOYSA-N Cc1n[s]cn1 Chemical compound Cc1n[s]cn1 IBANRDPEOYZVGW-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N Cc1ncc[nH]1 Chemical compound Cc1ncc[nH]1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- ZCHCHJQEWYIJDQ-UHFFFAOYSA-N Cc1ncc[o]1 Chemical compound Cc1ncc[o]1 ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N Cc1ncc[s]1 Chemical compound Cc1ncc[s]1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- IRIHSZDBTACXCT-UHFFFAOYSA-N Cc1ncccc1F Chemical compound Cc1ncccc1F IRIHSZDBTACXCT-UHFFFAOYSA-N 0.000 description 1
- RGTBLCLLSZPOKR-UHFFFAOYSA-N Cc1ncn[o]1 Chemical compound Cc1ncn[o]1 RGTBLCLLSZPOKR-UHFFFAOYSA-N 0.000 description 1
- QLXOJLUHWBDVKZ-UHFFFAOYSA-N Cc1ncn[s]1 Chemical compound Cc1ncn[s]1 QLXOJLUHWBDVKZ-UHFFFAOYSA-N 0.000 description 1
- YIUOAAUFVBZQPM-UHFFFAOYSA-N Cc1ncncn1 Chemical compound Cc1ncncn1 YIUOAAUFVBZQPM-UHFFFAOYSA-N 0.000 description 1
- QZHLOBBAAIAWLC-UHFFFAOYSA-N INCc1ccccn1 Chemical compound INCc1ccccn1 QZHLOBBAAIAWLC-UHFFFAOYSA-N 0.000 description 1
- GBFYTHUILBYBRI-UHFFFAOYSA-N NC(CCN1Cc2ccccc2)=CC1=O Chemical compound NC(CCN1Cc2ccccc2)=CC1=O GBFYTHUILBYBRI-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-O O=C1[NH2+]CCC1 Chemical compound O=C1[NH2+]CCC1 HNJBEVLQSNELDL-UHFFFAOYSA-O 0.000 description 1
- DHYKCSGCXKYSJG-UHFFFAOYSA-N OC(CC1)CN1C1CC1 Chemical compound OC(CC1)CN1C1CC1 DHYKCSGCXKYSJG-UHFFFAOYSA-N 0.000 description 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-O OC1C[NH2+]CC1 Chemical compound OC1C[NH2+]CC1 JHHZLHWJQPUNKB-UHFFFAOYSA-O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73413905P | 2005-11-07 | 2005-11-07 | |
| PCT/US2006/043269 WO2007056330A1 (en) | 2005-11-07 | 2006-11-06 | Benzimidazole derivatives as gyrase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009514894A JP2009514894A (ja) | 2009-04-09 |
| JP2009514894A5 true JP2009514894A5 (https=) | 2009-10-22 |
Family
ID=37894258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008539114A Pending JP2009514894A (ja) | 2005-11-07 | 2006-11-06 | ジャイレース阻害剤としてのベンズイミダゾール誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8394803B2 (https=) |
| EP (1) | EP1948635A1 (https=) |
| JP (1) | JP2009514894A (https=) |
| CN (1) | CN101321744A (https=) |
| AU (1) | AU2006311729A1 (https=) |
| CA (1) | CA2626685A1 (https=) |
| WO (1) | WO2007056330A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7582641B2 (en) | 2003-01-31 | 2009-09-01 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
| US8404852B2 (en) | 2003-01-31 | 2013-03-26 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| US7569591B2 (en) | 2003-01-31 | 2009-08-04 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
| US8193352B2 (en) | 2003-01-31 | 2012-06-05 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
| US7618974B2 (en) | 2003-01-31 | 2009-11-17 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
| EP2229379A2 (en) | 2007-12-07 | 2010-09-22 | Vertex Pharmaceuticals Incorporated | Solid forms of 1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1h-benzo[d]imidazol-2-yl)urea |
| WO2010027583A1 (en) | 2008-09-03 | 2010-03-11 | Universal Display Corporation | Phosphorescent materials |
| GB0821913D0 (en) | 2008-12-02 | 2009-01-07 | Price & Co | Antibacterial compounds |
| AU2010229142A1 (en) * | 2009-03-23 | 2011-10-13 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| US9221765B2 (en) | 2009-06-10 | 2015-12-29 | North Carolina State University | Inhibition and dispersion of bacterial biofilms with benzimidazole derivatives |
| RU2012146246A (ru) | 2010-03-31 | 2014-05-10 | Актелион Фармасьютиклз Лтд | Антибактериальные производные изохинолин-3-илмочевины |
| ES2803556T3 (es) | 2010-06-01 | 2021-01-27 | Summit Oxford Ltd | Compuestos para el tratamiento de enfermedades asociadas a clostridium difficile |
| WO2011151617A1 (en) | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile associated disease |
| WO2011151620A1 (en) | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile associated disease |
| WO2011151618A2 (en) | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile-associated disease |
| WO2011151619A1 (en) | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile associated disease |
| KR101882172B1 (ko) | 2011-01-14 | 2018-07-26 | 스페로 트리넴, 인코포레이티드 | 자이라제 및 토포이소머라제 ⅳ 억제제의 제조방법 |
| BR112013017977A2 (pt) | 2011-01-14 | 2019-09-24 | Vertex Pharma | formas sólidas de inibidor de girase (r) 1-etil-3-[5-[2-{1-hidroxi-1-metil-etil}pirimidin-5-il]-7-(tetrai-drofuran-2-il)-1h-benzimidazol-2-il]ureia |
| RU2609259C2 (ru) | 2011-01-14 | 2017-01-31 | Сперо Тринем, Инк. | Пиримидиновые ингибиторы гиразы и топоизомеразы iv |
| US8476281B2 (en) | 2011-01-14 | 2013-07-02 | Vertex Pharmaceuticals Incorporated | Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea |
| AR088729A1 (es) | 2011-03-29 | 2014-07-02 | Actelion Pharmaceuticals Ltd | Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica |
| CN103702994B (zh) * | 2011-06-20 | 2016-03-23 | 沃泰克斯药物股份有限公司 | 旋转酶和拓扑异构酶抑制剂的磷酸酯 |
| WO2014014845A1 (en) | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases |
| US9018216B2 (en) | 2012-07-18 | 2015-04-28 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof |
| US9079935B2 (en) | 2012-08-13 | 2015-07-14 | The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas | Reducing risk of contracting Clostridium-difficile associated disease |
| US20170007615A1 (en) | 2014-02-03 | 2017-01-12 | Biota Europe Ltd | Antibacterial Compounds |
| CN104945329B (zh) * | 2014-03-24 | 2017-09-01 | 中国医学科学院医药生物技术研究所 | 抗结核药物 |
| WO2016127102A2 (en) | 2015-02-06 | 2016-08-11 | Ernesto Abel-Santos | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis |
| CA3057431A1 (en) | 2017-03-24 | 2018-09-27 | Taisho Pharmaceutical Co., Ltd. | 2(1h)-quinolinone derivative |
| IL289453B2 (en) | 2019-07-17 | 2026-03-01 | Summit Oxford Ltd | Process for preparing ridinilazole and its crystalline forms |
| CN111658646B (zh) * | 2020-06-28 | 2021-03-02 | 河南工业大学 | 2,6-双(2-苯并咪唑基)吡啶在制备耐碳青霉烯类铜绿假单胞菌感染药物中的应用 |
| GB202100471D0 (en) | 2021-01-14 | 2021-03-03 | Summit Oxford Ltd | Preparation of antibacterial compounds |
| GB202100470D0 (en) | 2021-01-14 | 2021-03-03 | Summit Oxford Ltd | Solid tablet dosage for of ridinilazole |
| WO2023039159A2 (en) | 2021-09-09 | 2023-03-16 | Abel Santos Ernesto | Inhibitors of c. difficile spore germination |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60131015T2 (de) * | 2000-12-15 | 2008-07-10 | Vertex Pharmaceuticals Inc., Cambridge | Bakterielle gyrase-hemmer und deren verwendung |
| PL374191A1 (en) * | 2002-06-13 | 2005-10-03 | Vertex Pharmaceuticals Incorporated | 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections |
| US7569591B2 (en) * | 2003-01-31 | 2009-08-04 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
| US7582641B2 (en) | 2003-01-31 | 2009-09-01 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
| US7618974B2 (en) | 2003-01-31 | 2009-11-17 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
| AR042956A1 (es) * | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
-
2006
- 2006-11-06 JP JP2008539114A patent/JP2009514894A/ja active Pending
- 2006-11-06 US US11/593,418 patent/US8394803B2/en not_active Expired - Fee Related
- 2006-11-06 WO PCT/US2006/043269 patent/WO2007056330A1/en not_active Ceased
- 2006-11-06 CN CNA2006800454440A patent/CN101321744A/zh active Pending
- 2006-11-06 AU AU2006311729A patent/AU2006311729A1/en not_active Abandoned
- 2006-11-06 EP EP06827594A patent/EP1948635A1/en not_active Withdrawn
- 2006-11-06 CA CA002626685A patent/CA2626685A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009514894A5 (https=) | ||
| CA2513463A1 (en) | Gyrase inhibitors and uses thereof | |
| JP2005533061A5 (https=) | ||
| RU2005100516A (ru) | Производные 2-уреидо-6-гетероарил-3н-бензимидазол-6-карбоновой кислоты и родственные соединения в качестве ингибиторов гиразы и/или топоизомеразы iv для лечения бактериальных инфекций | |
| CA2577758A1 (en) | Gyrase inhibitors and uses thereof | |
| ES2215713T3 (es) | Feniloxazolidinonas sustituidas heterobiciclicas antibacterianas. | |
| ES2576298T3 (es) | Ésteres de fosfato de inhibidores de girasa y topoisomerasa | |
| ES2545516T3 (es) | Inhibidores de la pirimidina girasa y la topoisomerasa IV | |
| JP2007514782A5 (https=) | ||
| ES2705923T3 (es) | Formas sólidas de inhibidor de girasa (R)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1H-bencimidazol-2-il]urea | |
| JP2009514894A (ja) | ジャイレース阻害剤としてのベンズイミダゾール誘導体 | |
| CN111566099A (zh) | 抗菌化合物 | |
| JP2015514063A (ja) | 抗菌化合物 | |
| JP2014500235A5 (https=) | ||
| US9399639B2 (en) | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use | |
| CN113614092A (zh) | 提供抗革兰氏阳性细菌增强的抗菌活性的组合物及其用途 | |
| US20130281442A1 (en) | Compounds for Treatment of Bovine Mastitis | |
| EP1411949A2 (en) | 8/17 heterocyclic compounds and uses thereof as d-alanyl-d-alanine ligase inhibitors | |
| JP2009503025A5 (https=) | ||
| CA2797281A1 (en) | Aza-indole derivatives useful as modulators of faah | |
| RU2007121581A (ru) | Макролоны-аминозамещенные хинолоны | |
| CA2548666A1 (en) | Amino-benzimidazoles derivatives as inhibitors of respiratory syncytial virus replication | |
| TW201904970A (zh) | 抗微生物劑及製造及使用方法 | |
| US20240043467A1 (en) | 5'-substituted nucleoside monophosphates, prodrugs thereof, and uses related thereto | |
| JP2006506319A5 (https=) |